Skip to main content
. 2021 Jan 15;106(4):510–517. doi: 10.1136/bjophthalmol-2020-317949

Table 1.

Primary uveal melanoma presenting with metastasis versus with no metastasis

Characteristics AJCC stage IV uveal melanoma at initial presentation
(group M) n=69
AJCC stage I–III uveal melanoma at initial presentation
(group N) n=3541
Choroidal Ciliary body Iris Choroidal Ciliary body Iris
Sample 55 (80%) 11 (16%) 3 (4%) 3097 (87%) 266 (8%) 178 (5%)
Tumour thickness
(mm)
Mean (SD) 8.3 (4.8) 9.6 (3.4) N/A 5.7 (3.0) 6.0 (3.0) N/A
Median (range) 7.7 (2-0–24.5) 11.0 (2.7–14.7) N/A 5.0 (2.0–23.0) 5.6 (2.0–16.0) N/A
Largest basal diameter (mm)* Mean (SD) 14.4 (4.7) 10.2 (2.6) 6.8 (2.0) 12.1 (3.8) 10.4 (2.8) 3.9 (2.7)
Median (range) 15.0 (2.9–25.0) 9.1 (6.0–13.8) 6.4 (5.0–9.0) 12.0 (2.0–30.0) 11.0 (2.0–14.0) 3.0 (0.5–19.0)
T-category T1 5 (9%) 1 (9%) 2 (67%) 944 (31%) 87 (33%) 92 (52%)
T2 18 (33%) 2 (18%) 0 (0%) 1101 (35%) 107 (40%) 84 (47%)
T3 16 (29%) 7 (64%) 0 (0%) 832 (27%) 67 (25%) 0 (0%)
T4 16 (29%) 1 (9%) 1 (33%) 220 (7%) 5 (2%) 2 (1%)
ESE 6 (11%) 5 (45%) 1 (33%) 48 (2%) 16 (6%) 2 (1%)
CBI 11 (20%) 11 (100%) 1 (33%) 248 (8%) 266 (100%) 88 (49%)
ESE and CBI 4 (7%) 5 (45%) 1 (33%) 20 (1%) 16 (100%) 2 (1%)

*In the case of iris melanoma, only the largest basal diameter was mentioned.

AJCC, American Joint Committee on Cancer, 8th edition; CBI, ciliary body involvement; ESE, extrascleral extension.

HHS Vulnerability Disclosure